Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1SWN3
|
|||
| Drug Name |
Afegostat
|
|||
| Synonyms |
Isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL; 169105-89-9; iso-Fagomine; D-Isofagomine; UNII-G23AP190YS; 5-HYDROXYMETHYL-3,4-DIHYDROXYPIPERIDINE; CHEMBL206468; G23AP190YS; IFM; 5-Hydroxymethyl-3,4-piperidinediol; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL HYDROCHLORIDE; Afegostat [USAN:INN]; 1oif; Afegostat (USAN/INN); SCHEMBL581577; GTPL7410; 3,4-piperidinediol, 5-(hydroxymethyl)-, (3R,4R,5R)-; DTXSID20168651; 5-Hydroxymethylpiperidine-3,4-diol; ZINC3813668; BDBM50182801; AKOS006348872; DB04545; HY-14829; CS-0003581; D09576; Q21396373; (3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8; Afegostat; isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gaucher disease [ICD-11: 5C56.0Y; ICD-9: 272.7] | Discontinued in Phase 2 | [1] | |
| Company |
Amicus Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H13NO3
|
|||
| Canonical SMILES |
C1C(C(C(CN1)O)O)CO
|
|||
| InChI |
1S/C6H13NO3/c8-3-4-1-7-2-5(9)6(4)10/h4-10H,1-3H2/t4-,5-,6-/m1/s1
|
|||
| InChIKey |
QPYJXFZUIJOGNX-HSUXUTPPSA-N
|
|||
| CAS Number |
CAS 169105-89-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucosylceramidase (GBA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Other glycan degradation | |||
| Sphingolipid metabolism | ||||
| Metabolic pathways | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.